



Uscom

ASX MEDIA RELEASE

Completion of small share parcels consolidation

SYDNEY, Australia, 30 March 2022: Uscom Limited (ASX code: UCM) (the **Company** or **Uscom**) has successfully completed its small share parcels consolidation. A total of 269,199 UCM shares have been sold on market and proceeds are being returned proportionately to the 121 shareholders who participated.

The shares were sold for an average of \$0.089 per share and the share register will forward the proceeds to each shareholder.

The small share parcels consolidation provided a commercially feasible pathway for investors with small parcels of UCM shares to transact without incurring brokerage costs. A small share parcel was defined as less \$500 in value at the time of the offer. Uscom has met the costs of the transaction.

This announcement is approved for release to the ASX by the Board of Uscom Limited.

About Uscom

Uscom Limited (UCM): An ASX listed innovative medical technology company specialising in development and marketing of premium non-invasive cardiovascular and pulmonary medical devices. Uscom has a mission to demonstrate leadership in science and create noninvasive devices that assist clinicians improve clinical outcomes. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the **USCOM 1A** advanced haemodynamic monitor, Uscom **BP+** central blood pressure monitor, and the Uscom **SpiroSonic** digital ultrasonic spirometers. Uscom devices are premium resolution, noninvasive devices which deploy innovative and practice leading technologies approved or submitted for FDA, CE, CFDA and TGA regulatory approval and marketing into global distribution networks. **The USCOM 1A:** A simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The **USCOM 1A** device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotropes and vasoactive cardiovascular therapy.

The Uscom BP+: A supra-systolic oscillometric central blood pressure monitor which measures blood pressure and blood pressure waveforms at the heart, as well as in the arm, information only previously available using invasive cardiac catheterisation. The Uscom **BP+** replaces conventional and more widespread sub-systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom **BP+** provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The **BP+** is simple to use and requires no complex training with applications in hypertension and pre-eclampsia, heart failure, intensive care, general practice and home care. The Uscom **BP+** is supported by the proprietary **BP+ Reporter**, an innovative stand alone software solution that provides a digital platform to archive patient examinations and images, trend measure progress over time, analyse pulse pressure waves and generate summary reports.

Uscom SpiroSonic digital multi-path ultrasonic spirometers: High fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. The **SpiroSonic** spirometers, **FLO**, **SMART**, and **AIR**, require no calibration, are durable, simple to disinfect, and are simple, inexpensive and accurate to use providing research quality pulmonary function testing in hand held devices that can be used in research,



Uscom

ASX MEDIA RELEASE

clinical and home care environments. The devices can be coupled with mobileSpiroSonic APP and proprietary **SpiroSonic** software, **SpiroReporter**, with wireless interfacing to provide remote tele-monitoring of pulmonary disease. The devices are specialised for assessment of asthma, COPD, sleep disordered breathing, industrial lung disease and COVID monitoring for pulmonary fibrosis.

VENTITEST: Digital ultrasonic ventilator calibration solution is a new system for calibrating ventilators. All ventilators and respiratory support devices require calibration to maintain the accuracy with which they measure the pressure, flow and volume of air they deliver. **VENTITEST** and **VENTITEST-S**, based on advanced SpiroSonic technology provides a calibration solution that provides for simple and accurate calibration, archiving, analysis and reporting and optimal ventilation performance.

For more information, please visit: www.uscom.com.au

Authorised by:

Rob Phillips
Executive Chairman
rob@uscom.com.au

Brett Crowley
Company Secretary

This announcement is approved for release to the ASX by the Board of Uscom Limited.